Compare BKSY & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BKSY | IMMP |
|---|---|---|
| Founded | 2013 | 1987 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 839.0M | 42.4M |
| IPO Year | 2019 | 2012 |
| Metric | BKSY | IMMP |
|---|---|---|
| Price | $23.24 | $0.26 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 3 |
| Target Price | ★ $28.50 | $5.50 |
| AVG Volume (30 Days) | ★ 823.4K | 324.8K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.72 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $27.03 | $445.09 |
| Revenue Next Year | $29.21 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.41 | $0.26 |
| 52 Week High | $52.88 | $3.53 |
| Indicator | BKSY | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 49.80 | 29.26 |
| Support Level | $20.05 | N/A |
| Resistance Level | $24.35 | $0.40 |
| Average True Range (ATR) | 1.31 | 0.02 |
| MACD | 0.37 | -0.01 |
| Stochastic Oscillator | 84.68 | 7.86 |
BlackSky Technology Inc is a space-based technology company that delivers real-time imagery, analytics and high-frequency monitoring of the worlds critical and strategic locations, economic assets, and events. By taking a software-first technology approach, Company is delivering real-time space-based intelligence at disruptive speed, scale and economics. Companies single operating and reportable segment, provided space-based intelligence products and services through three integrated revenue streams-space-based intelligence & AI services, mission solutions, and technology programs. Geographically, the company operates in United States and Rest of world.
Immutep Ltd is a clinical-stage biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.